| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2001 | WO2001001923A2 Composition based on fluorinated polymer and alpha-hydroxy-acid salt for topical use for skin protection |
| 01/11/2001 | WO2001001922A2 Use of substance p antagonists for the treatment of adenocarcinoma |
| 01/11/2001 | WO2001001797A1 Oral form of administration |
| 01/11/2001 | WO2000066604A3 L-ribo-lna analogues |
| 01/11/2001 | WO2000066108A3 Anticonvulsant derivatives useful in treating cocaine dependency |
| 01/11/2001 | WO2000063364A3 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 01/11/2001 | WO2000062801A3 Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv) |
| 01/11/2001 | WO2000062800A3 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 01/11/2001 | WO2000062657A3 Improvement of t cell mediated immunity |
| 01/11/2001 | WO2000061546A3 Novel aryl-chloro-ethyl ureas |
| 01/11/2001 | WO2000061543A3 Esters of l-carnitine or alkanoyl l-carnitines |
| 01/11/2001 | WO2000061189A3 Water-soluble compositions of bioactive lipophilic compounds |
| 01/11/2001 | WO2000061167A3 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS |
| 01/11/2001 | WO2000061068A3 Anthelmintic compositions |
| 01/11/2001 | WO2000059904A3 Compounds and methods to treat cardiac failure and other disorders |
| 01/11/2001 | WO2000059515A3 Immunomodulating polymers |
| 01/11/2001 | WO2000059485A3 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor |
| 01/11/2001 | WO2000057868A3 Use of carbamamic acid derivatives for the treatment of viral infections |
| 01/11/2001 | WO2000057851A3 High potency dihydroergotamine compositions |
| 01/11/2001 | WO2000057840A3 Dermatological topical composition |
| 01/11/2001 | WO2000056345A3 Methods for limiting scar and adhesion formation |
| 01/11/2001 | WO2000054729A3 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/11/2001 | WO2000053596A3 Imidazole compounds as histamine h3 ligands |
| 01/11/2001 | WO2000053169A8 Method of inhibiting a chaperone protein |
| 01/11/2001 | WO2000051603A3 Compositions of remifentanil |
| 01/11/2001 | WO2000051579A3 Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity |
| 01/11/2001 | WO2000051546A3 Bupropion metabolites and methods of their synthesis and use |
| 01/11/2001 | WO2000048581A3 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 01/11/2001 | WO2000038667A3 Prostaglandin e agonists for treatment of glaucoma |
| 01/11/2001 | DE19932315A1 Benzoylpyridazine Benzoylpyridazine |
| 01/11/2001 | DE19932314A1 Benzofuranderivate Benzofuran derivatives |
| 01/11/2001 | DE19931206A1 Relaxing, or increasing cyclic adenosine monophosphate concentration in smooth muscular tissue, e.g. by administration of cAMP phosphodiesterase inhibitors, dipyridamole or sildenafil |
| 01/11/2001 | DE19930177A1 Intermolekular assoziierende Verbindungen und diese umfassende Aggregate Inter-molecular compounds and associating this comprehensive aggregates |
| 01/11/2001 | DE19930030A1 Orale Darreichungsform The oral dosage form |
| 01/11/2001 | DE19929995A1 Treating or preventing female ailments, e.g. premenstrual syndrome, dysmenorrhea and associated headaches or constipation, by administration of creatine or its derivative |
| 01/11/2001 | DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the |
| 01/11/2001 | DE19916108C1 Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung With sugar residues substituted 1,4-benzothiazepine-1,1-dioxide derivatives, processes for their preparation and their use |
| 01/11/2001 | CA2643231A1 Norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | CA2527931A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 01/11/2001 | CA2380875A1 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | CA2380866A1 Selective npy (y5) antagonists |
| 01/11/2001 | CA2378521A1 Pharmaceutical tablets |
| 01/11/2001 | CA2378467A1 Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| 01/11/2001 | CA2378389A1 Therapeutic agents |
| 01/11/2001 | CA2377932A1 Control of gene expression in eukaryotic cells |
| 01/11/2001 | CA2377931A1 Novel mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | CA2377784A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | CA2377780A1 Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| 01/11/2001 | CA2377734A1 Heparin compositions that inhibit clot associated coagulation factors |
| 01/11/2001 | CA2376965A1 Peptide boronic acid inhibitors of hepatitis c virus protease |
| 01/11/2001 | CA2376944A1 A substantially crystalline form of melagatran |
| 01/11/2001 | CA2376707A1 Process for the preparation of substituted ¬1,4|diazepino¬6,7,1-hi|indol-4-ones |
| 01/11/2001 | CA2376681A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/11/2001 | CA2376673A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/11/2001 | CA2376657A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 01/11/2001 | CA2376495A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 01/11/2001 | CA2375751A1 Use of cortisol antagonists in the treatment for heat failure |
| 01/11/2001 | CA2375157A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | CA2375091A1 Crystals of benzimidazole compounds |
| 01/11/2001 | CA2374931A1 Solid preparations containing paroxetine |
| 01/11/2001 | CA2374358A1 Methods and compositions for regulating gut motility and food intake |
| 01/11/2001 | CA2373960A1 Use of substance p antagonists for the treatment of adenocarcinoma |
| 01/11/2001 | CA2373953A1 A synergistic combination: gabapentin and pregabalin |
| 01/11/2001 | CA2373940A1 Medicinal compositions for treating colorectal cancer |
| 01/11/2001 | CA2373883A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | CA2373882A1 Compounds having cytokine inhibitory activity |
| 01/11/2001 | CA2373881A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | CA2373879A1 Antiviral therapy |
| 01/11/2001 | CA2373877A1 Novel pharmaceutical combination with analgesic action containing paracetamol and buspirone |
| 01/11/2001 | CA2373844A1 Cosmetic skin care compositions containing cumic alcohol |
| 01/11/2001 | CA2341984A1 Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives |
| 01/11/2001 | CA2341253A1 Telomerase inhibitors and methods of their use |
| 01/10/2001 | EP1067386A2 Inhibition of tau-tau-association |
| 01/10/2001 | EP1067136A1 New peptide derivatives |
| 01/10/2001 | EP1067130A1 Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient |
| 01/10/2001 | EP1067109A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| 01/10/2001 | EP1066854A2 Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds |
| 01/10/2001 | EP1066834A2 Pharmaceutical compositions comprising a phagocyte-modulating agent |
| 01/10/2001 | EP1066832A1 Preventives and remedies for ischemic reflow disorder |
| 01/10/2001 | EP1066830A2 Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/10/2001 | EP1066829A1 Stable microemulsions for administration of fatty acids, and use thereof |
| 01/10/2001 | EP1066828A1 Medicaments |
| 01/10/2001 | EP1066822A1 Composition for treating dandruffs in hair and scalp based on an antidandruff agent and a hydroxy-acid |
| 01/10/2001 | EP1066821A1 Topical cosmetic product containing benzaldoxims |
| 01/10/2001 | EP1066816A1 Agents promoting laminin production in skin cells |
| 01/10/2001 | EP1066761A2 Compositions containing fat-soluble substances in a carbohydrate matrix |
| 01/10/2001 | EP1066377A1 Methods for prevention and treatment of cancer |
| 01/10/2001 | EP1066319A1 Production methods and uses of a retrovirus |
| 01/10/2001 | EP1066316A1 Cinnamic acid derivatives having cell adhesion modulating activity |
| 01/10/2001 | EP1066307A1 3',3'-n-bis-substituted macrolide lhrh antagonists |
| 01/10/2001 | EP1066305A2 Sucrose-n-alkyl-asparaginates, production and use thereof |
| 01/10/2001 | EP1066304A1 Macrolide lhrh antagonists |
| 01/10/2001 | EP1066297A1 Phosphinic acid derivatives |
| 01/10/2001 | EP1066294A1 Novel process for the fermentative production of cephalosporin |
| 01/10/2001 | EP1066293A2 New porphyrins and their use |
| 01/10/2001 | EP1066292A1 Metallocorrinoids as biologically compatible carriers of pharmacological agents |
| 01/10/2001 | EP1066290A1 PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR |
| 01/10/2001 | EP1066288A2 Novel compounds |
| 01/10/2001 | EP1066287A1 Azatricyclic compounds |
| 01/10/2001 | EP1066286A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |